Quantcast

Latest Temozolomide Stories

2010-06-05 08:00:00

CHICAGO, June 5 /PRNewswire/ -- Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but...

2010-05-21 06:30:00

MISSISSAUGA, May 21 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced that three poster presentations and a published abstract will report results from several global nimotuzumab trials in adults with Glioblastoma Multiforma and in patients with head and neck cancer at the American Society of Clinical Oncology annual meeting held from June 4-8, 2010 in Chicago, Illinois. The trials are being conducted by Oncoscience AG (Wedel, Germany), YM's licensee for...

2009-12-08 20:03:10

Small molecule plus TMZ appears to lower tumor resistance University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells. More research is needed before the therapy can be tested in patients, but the discovery in human colon cancer cell lines and mice with established human tumors suggests that the addition of a small molecule to the cancer drug...

2009-10-26 07:00:00

MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23,...

2009-10-01 13:58:00

Chemotherapy alone is just as effective as radiation / New positive prognostic factor found Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Zrich showed that...

2009-09-28 08:00:00

NEW YORK, Sept. 28 /PRNewswire/ -- NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures. "We are very pleased that Pfizer, Johnson & Johnson Development Corporation and Index have taken an interest in...

2009-08-11 15:23:00

SAN MARINO, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Dr. Karen Newell, Ph. D., the lead researcher for bio technology company Viral Genetics (Pink Sheets: VRAL), will address the 4th Annual Aspen Symposium on Brain Tumor Immuno- and Stem Cell Therapy. Her presentation will highlight the potential for combining chemotherapy with compounds that interfere with the ability of brain tumor cells to generate the energy needed to repair chemotherapy induced DNA damage. This repair mechanism is...

2009-08-05 14:30:00

Simulations point to changes in water depth and currents as increasing likelihood of rogue wavesTwo forms of skin and brain cancer respond very poorly to chemotherapy and radiation: melanoma and glioblastoma multiforme brain cancer.Both are the focus of an intensive effort in the department of nutritional sciences at The University of Arizona to find natural, biologically active compounds that will sensitize the cancerous tumors to therapy without damaging normal tissue. By using the...

2009-08-04 07:52:00

VOORHEES, N.J., Aug. 4 /PRNewswire/ -- Treatment of glioblastoma (GBM), the most common type of glioma, presents many challenges. More than 50% of patients die of disease progression within 18 months of diagnosis. Current treatment includes the use of temozolomide-based chemotherapy, both concurrently with and after completion of radiotherapy. As healthcare professionals gain a better understanding of the molecular biology of GBM and utilize targeted therapies more frequently, there is hope...

2009-07-15 06:30:00

CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation by Dr. Jacqueline Parker et al. entitled "Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment with Either Therapy Alone" was made yesterday at the 28th American Society for Virology (ASV) Annual Meeting. The meeting is being held in...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related